Skip to main content
. Author manuscript; available in PMC: 2023 May 4.
Published in final edited form as: Cancer Immunol Res. 2023 May 3;11(5):629–645. doi: 10.1158/2326-6066.CIR-22-0655

Figure 3. Combination PD-1/CTLA-4 checkpoint blockade promotes CD8+ T cell-dependent therapeutic response in EGFR-WT but not in EGFRvIII GBM.

Figure 3.

A) Treatment scheme of GBM mice. B) Left, Kaplan-Meier analysis of EGFR-WT GBM mice treated with indicated antibodies. Median survival (ms) in days. * p=0.0158, log-rank (Mantel Cox) test. Right, BLI outputs over time of a subset of mice from left. C) Kaplan-Meier analysis of EGFR-WT mice treated with indicated antibodies, *p=0.0001, log-rank (Mantel Cox) test. D) Left, Kaplan-Meier analysis of EGFRvIII GBM mice treated with indicated antibodies. Right, BLI outputs over time of a subset of mice from left. E) Flow cytometry of relative amounts of EGFR+ tumor cells in GBMs. Unbracketed; compared to IgG control. F-G) Relative levels of cleaved caspase 3 (CC3) (F) and Ki-67 proliferative index (G) on GBM tissue from the indicated treatments. n=3 GBMs and >3 serial sections stained for CC3 or Ki-67. Mean±SEM of biological replicates. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, unpaired t test, two-tailed.